Active, Not Recruiting
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer - CA209-078
Updated:
7 October, 2022
|
ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Disease progression experienced during or after one prior platinum containing doublet chemotherapy - Stage IIIb/IV or recurrent disease - Male and Female ≥ 18 years of age - Measurable disease per RECIST 1.1 - Performance Status ≤ 1 Exclusion Criteria: - History of Carcinomatous meningitis - Active Central nervous system (CNS) metastases - History of auto immune diseases - Prior treatment with Docetaxel - Prior treatment with ipilimumab or any drug targeting T-Cell costimulation or checkpoint pathways
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information